Oral octreotide capsules for acromegaly treatment: application of clinical trial insights to real-world use

References

• Fleseriu M, Langlois F, Lim DST, et al. Acromegaly: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol. 2022;10(11):804–826. doi:10.1016/S2213-8587(22)00244-3
   PubMed Web of Science ®Google Scholar
• Colao A, Grasso LFS, Giustina A, et al. Acromegaly. Nat Rev Dis Primers. 2019;5(1):20. doi: 10.1038/s41572-019-0071-6
   PubMed Web of Science ®Google Scholar
• Biermasz NR, Smit JW, Pereira AM, et al. Acromegaly caused by growth hormone-releasing hormone-producing tumors: long-term observational studies in three patients. Pituitary. 2007;10(3):237–249. doi: 10.1007/s11102-007-0045-7
   PubMed Web of Science ®Google Scholar
• Asa SL, Mete O. Hypothalamic endocrine tumors: an update. J Clin Med. 2019;8(10):1741. doi: 10.3390/jcm8101741
   PubMed Web of Science ®Google Scholar
• Krug S, Boch M, Rexin P, et al. Acromegaly in a patient with a pulmonary neuroendocrine tumor: case report and review of current literature. BMC Res Notes. 2016;9(1):326. doi: 10.1186/s13104-016-2132-1
   PubMedGoogle Scholar
• Macfarlane DP, Leese GP. Hypoglycaemia, phaeochromocytoma and features of acromegaly: a unifying diagnosis? QJM. 2010;104(11):983–986. doi: 10.1093/qjmed/hcq219
   PubMed Web of Science ®Google Scholar
• Melmed S. Acromegaly pathogenesis and treatment. J Clin Invest. 2009;119(11):3189–3202. doi:10.1172/JCI39375
   PubMed Web of Science ®Google Scholar
• Crisafulli S, Luxi N, Sultana J, et al. Global epidemiology of acromegaly: a systematic review and meta-analysis. Eur J Endocrinol. 2021;185(2):251–263. doi: 10.1530/EJE-21-0216
   PubMed Web of Science ®Google Scholar
• Lavrentaki A, Paluzzi A, Wass JA, et al. Epidemiology of acromegaly: review of population studies. Pituitary. 2017;20(1):4–9. doi: 10.1007/s11102-016-0754-x
   PubMed Web of Science ®Google Scholar
• Chanson P, Salenave S. Acromegaly. Orphanet J Rare Dis. 2008;3(1):17. doi: 10.1186/1750-1172-3-17
   PubMedGoogle Scholar
• Fleseriu M, Biller BMK, Freda PU, et al. A pituitary society update to acromegaly management guidelines. Pituitary. 2021;24(1):1–13. doi: 10.1007/s11102-020-01091-7
   PubMed Web of Science ®Google Scholar
• Cheok SK, Carmichael JD, Zada G. Management of growth hormone-secreting pituitary adenomas causing acromegaly: a practical review of surgical and multimodal management strategies for neurosurgeons. J Neurosurg. 2023;140(5): 1285–1294. doi: 10.3171/2023.8.JNS221975
   PubMedGoogle Scholar
• Slagboom TNA, van Bunderen CC, De Vries R, et al. Prevalence of clinical signs, symptoms and comorbidities at diagnosis of acromegaly: a systematic review in accordance with PRISMA guidelines. Pituitary. 2023;26(4):319–332. doi:10.1007/s11102-023-01322-7
   PubMed Web of Science ®Google Scholar
• Reid TJ, Post KD, Bruce JN, et al. Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under-recognized and under-diagnosed. Clin Endocrinol (Oxf). 2010;72(2):203–208. doi:10.1111/j.1365-2265.2009.03626.x
   PubMed Web of Science ®Google Scholar
• Demir AN, Sulu C, Kara Z, et al. Changing presentation of acromegaly in half a century: a single-center experience. Pituitary. 2023;26(5):573–582. doi: 10.1007/s11102-023-01344-1
   PubMed Web of Science ®Google Scholar
• Gadelha MR, Kasuki L, Lim DST, et al. Systemic complications of acromegaly and the impact of the current treatment landscape: an update. Endocr Rev. 2019;40(1):268–332. doi:10.1210/er.2018-00115
   PubMed Web of Science ®Google Scholar
• Caron P, Brue T, Raverot G, et al. Signs and symptoms of acromegaly at diagnosis: the physician’s and the patient’s perspectives in the ACRO-POLIS study. Endocrine. 2019;63(1):120–129. doi: 10.1007/s12020-018-1764-4
   PubMed Web of Science ®Google Scholar
• Melmed S, Bronstein MD, Chanson P, et al. A consensus statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol. 2018;14(9):552–561. doi: 10.1038/s41574-018-0058-5
   PubMed Web of Science ®Google Scholar
• Bolfi F, Neves AF, Boguszewski CL, et al. Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis. Eur J Endocrinol. 2018;179(1):59–71. doi:10.1530/EJE-18-0255
   PubMed Web of Science ®Google Scholar
• Kim J, Hong N, Choi J, et al. Sex differences in mortality in patients with acromegaly: a nationwide cohort study in Korea. Eur J Endocrinol. 2023;189(2):225–234. doi: 10.1093/ejendo/lvad106
   PubMed Web of Science ®Google Scholar
• Giustina A, Biermasz N, Casanueva FF, et al. Consensus on criteria for acromegaly diagnosis and remission. Pituitary. 2024;27(1):7–22. doi: 10.1007/s11102-023-01360-1
   PubMed Web of Science ®Google Scholar
• Giustina A, Barkhoudarian G, Beckers A, et al. Multidisciplinary management of acromegaly: a consensus. Rev Endocr Metab Disord. 2020;21(4):667–678. doi: 10.1007/s11154-020-09588-z
   PubMed Web of Science ®Google Scholar
• Mohyeldin A, Katznelson LJ, Hoffman AR, et al. Prospective intraoperative and histologic evaluation of cavernous sinus medial wall invasion by pituitary adenomas and its implications for acromegaly remission outcomes. Sci Rep. 2022;12(1):9919. doi: 10.1038/s41598-022-12980-1
   PubMed Web of Science ®Google Scholar
• Kasuki L, Lamback E, Antunes X, et al. Biomarkers of response to treatment in acromegaly. Expert Rev Endocrinol Metab. 2024;19(1):71–80. doi:10.1080/17446651.2023.2293107
   PubMed Web of Science ®Google Scholar
• Ghajar A, Jones PS, Guarda FJ, et al. Biochemical control in acromegaly with multimodality therapies: Outcomes from a pituitary center and changes over time. J Clin Endocrinol Metab. 2020;105(3):e532–543. doi: 10.1210/clinem/dgz187
   PubMed Web of Science ®Google Scholar
• Melmed S, Popovic V, Bidlingmaier M, et al. Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial. J Clin Endocrinol Metab. 2015;100(4):1699–1708. doi: 10.1210/jc.2014-4113
   PubMed Web of Science ®Google Scholar
• Starnoni D, Daniel RT, Marino L, et al. Surgical treatment of acromegaly according to the 2010 remission criteria: systematic review and meta-analysis. Acta Neurochir (Wien). 2016;158(11):2109–2121. doi:10.1007/s00701-016-2903-4
   PubMed Web of Science ®Google Scholar
• Rech MM, de Macedo Filho L, White AJ, et al. Machine learning models to forecast outcomes of pituitary surgery: a systematic review in quality of reporting and current evidence. Brain Sci. 2023;13(3):495. doi: 10.3390/brainsci13030495
   PubMed Web of Science ®Google Scholar
• Fleseriu M, Molitch M, Dreval A, et al. Disease and treatment-related burden in patients with acromegaly who are biochemically controlled on injectable somatostatin receptor ligands. Front Endocrinol (Lausanne). 2021;12:627711. doi: 10.3389/fendo.2021.627711
   PubMed Web of Science ®Google Scholar
• Fleseriu M, Dreval A, Bondar I, et al. Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial. Lancet Diabetes Endocrinol. 2022;10(2):102–111. doi: 10.1016/S2213-8587(21)00296-5
   PubMed Web of Science ®Google Scholar
• Carmichael JD, Bonert VS, Nuño M, et al. Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. J Clin Endocrinol Metab. 2014;99(5):1825–1833. doi:10.1210/jc.2013-3757
   PubMed Web of Science ®Google Scholar
• Adelman DT, Liebert KJ, Nachtigall LB, et al. Acromegaly: the disease, its impact on patients, and managing the burden of long-term treatment. Int J Gen Med. 2013;6:31–38. doi: 10.2147/IJGM.S38594
   PubMedGoogle Scholar
• Rowles SV, Prieto L, Badia X, et al. Quality of life (QOL) in patients with acromegaly is severely impaired: use of a novel measure of QOL: acromegaly quality of life questionnaire. J Clin Endocrinol Metab. 2005;90(6):3337–3341. doi:10.1210/jc.2004-1565
   PubMed Web of Science ®Google Scholar
• Melmed S. Pituitary-tumor endocrinopathies. N Engl J Med. 2020;382(10):937–950. doi:10.1056/NEJMra1810772
   PubMed Web of Science ®Google Scholar
• Colao A, Bronstein MD, Freda P, et al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab. 2014;99(3):791–799. doi: 10.1210/jc.2013-2480
   PubMed Web of Science ®Google Scholar
• Samson SL, Nachtigall LB, Fleseriu M, et al. Maintenance of acromegaly control in patients switching from injectable somatostatin receptor ligands to oral octreotide. J Clin Endocrinol Metab. 2020;105(10):e3785–3797. doi: 10.1210/clinem/dgaa526
   PubMed Web of Science ®Google Scholar
• Geer EB, Sisco J, Adelman DT, et al. Observed discordance between outcomes reported by acromegaly patients and their treating endocrinology medical provider. Pituitary. 2020;23(2):140–148. doi: 10.1007/s11102-019-01013-2
   PubMed Web of Science ®Google Scholar
• Geer EB, Sisco J, Adelman DT, et al. Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practice. BMC Endocr Disord. 2020;20(1):117. doi: 10.1186/s12902-020-00595-4
   PubMed Web of Science ®Google Scholar
• Brayden DJ, Maher S. Transient Permeation Enhancer® (TPE®) technology for oral delivery of octreotide: a technological evaluation. Expert Opin Drug Deliv. 2021;18(10):1501–1512. doi:10.1080/17425247.2021.1942838
   PubMed Web of Science ®Google Scholar
• Ballard ST, Hunter JH, Taylor AE. Regulation of tight-junction permeability during nutrient absorption across the intestinal epithelium. Annu Rev Nutr. 1995;15(1):35–55. doi: 10.1146/annurev.nu.15.070195.000343
   PubMedGoogle Scholar
• Higham CE, Atkinson AB, Aylwin S, et al. Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial. J Clin Endocrinol Metab. 2012;97(4):1187–1193. doi: 10.1210/jc.2011-2603
   PubMed Web of Science ®Google Scholar
• Kaniuka-Jakubowska S, Levy MJ, Pal A, et al. A study of acromegaly-associated headache with somatostatin analgesia. Endocr Relat Cancer. 2023;30(3). doi: 10.1530/ERC-22-0138
   PubMed Web of Science ®Google Scholar
• Giustina A, Mazziotti G, Cannavò S, et al. High-dose and high-frequency lanreotide autogel in acromegaly: a randomized, multicenter study. J Clin Endocrinol Metab. 2017;102(7):2454–2464. doi: 10.1210/jc.2017-00142
   PubMed Web of Science ®Google Scholar
• Bonert V, Mirocha J, Carmichael J, et al. Cost-effectiveness and efficacy of a novel combination regimen in acromegaly: a prospective, randomized trial. J Clin Endocrinol Metab. 2020;105(9):e3236–e3245. doi: 10.1210/clinem/dgaa444
   Web of Science ®Google Scholar
• Fleseriu M, Barkan A, Brue T, et al. Treatment patterns, adherence, persistence, and health care resource utilization in acromegaly: A real-world analysis. J Endocr Soc. 2023;7(10):bvad104. doi: 10.1210/jendso/bvad104
   PubMed Web of Science ®Google Scholar
• Kimball A, Dichtel LE, Yuen KCJ, et al. Quality of life after long-term biochemical control of acromegaly. Pituitary. 2022;25(3):531–539. doi: 10.1007/s11102-022-01224-0
   PubMed Web of Science ®Google Scholar
• Fleseriu M, Molitch M, Dreval A, et al. MPOWERED trial open-label extension: long-term efficacy and safety data for oral octreotide capsules in acromegaly. J Clin Endocrinol Metab. 2023;108(12):3214–3222. doi: 10.1210/clinem/dgad365
   PubMed Web of Science ®Google Scholar
• Samson SL, Nachtigall LB, Fleseriu M, et al. Durable biochemical response and safety with oral octreotide capsules in acromegaly. Eur J Endocrinol. 2022;187(6):733–741. doi: 10.1530/EJE-22-0220
   PubMed Web of Science ®Google Scholar
• MYCAPSSA. Prescribing Information. Chiasma. 2022.
   Google Scholar
• Macut D, Fleseriu M, Dreval A, et al. Outcomes in patients receiving oral octreotide capsules related to time from last SRL injection: analysis from the MPOWERED phase 3 study. In: Poster presented at: 20th Congress of the European Neuroendocrine Association; Lyon, France; [2022 Sep 7–10].
   Google Scholar
• MYCAPSSA. EPAR. Amryt Pharmaceuticals DAC. 2022.
   Google Scholar
• Tuvia S, Atsmon J, Teichman SL, et al. Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. J Clin Endocrinol Metab. 2012;97(7):2362–2369. doi: 10.1210/jc.2012-1179
   PubMed Web of Science ®Google Scholar
• Fleseriu M, Barkan A, Del Pilar Schneider M, et al. Prevalence of comorbidities and concomitant medication use in acromegaly: analysis of real-world data from the United States. Pituitary. 2022;25(2):296–307. doi: 10.1007/s11102-021-01198-5
   PubMed Web of Science ®Google Scholar
• Labadzhyan A, Nachtigall LB, Fleseriu M, et al. Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results. Pituitary. 2021;24(6):943–953. doi: 10.1007/s11102-021-01163-2
   PubMed Web of Science ®Google Scholar
• Fleseriu M, Dreval A, Pokramovich Y, et al. Predictors of response to oral octreotide capsules in patients with acromegaly in a large prospective international trial. Poster presented at: ENDO 2023; Chicago (IL); 2023 Jun 15–18.
   Google Scholar
• Fleseriu M, Dreval AV, Pokramovich Y, et al. Addition of cabergoline to oral octreotide capsules may improve biochemical control in patients with acromegaly who are inadequately controlled with monotherapy. J Endocr Soc. 2021;5(Suppl 1):A518–519. doi: 10.1210/jendso/bvab048.1058
   Google Scholar
• Chiasma, Inc. Data on file.
   Google Scholar
• Halstrom A, Dobri GA. Novel approach to management of acromegaly with de novo oral octreotide or combination therapy with cabergoline: a case series. Presented at: ENDO 2023; Chicago (IL); 2023 Jun 15.
   Google Scholar
• Yedinak C, Liebert KJP, Williams J. Case report: Optimizing the transition from injectable to oral treatment for acromegaly. J Clin Translational Endocrinol Case Rep. 2023;28:100145. doi:10.1016/j.jecr.2023.100145
   Google Scholar
• Mathioudakis N, Salvatori R. Management options for persistent postoperative acromegaly. Neurosurg Clin N Am. 2012;23(4):621–638. doi:10.1016/j.nec.2012.06.005
   PubMed Web of Science ®Google Scholar
• Zhao Z, Duan L, Gao D, et al. Efficacy and adverse events of octreotide long-acting release in acromegaly: a real-world retrospective study. Ann Transl Med. 2022;10(13):734. doi: 10.21037/atm-22-414
   PubMed Web of Science ®Google Scholar
• Fuchs Orenbach S, Haviv A. Results from the phase 1, randomized, open-label, cross-over study to evaluate pharmacokinetics of three escalating doses of oral octreotide capsules. In: Abstract. Presented at the 15th Annual Multidisciplinary Symposium NANETS 2022; Washington, D.C; [2022 Oct 27–29].
   Google Scholar
• Inayet N, Hayat J, Bano G, et al. Gastrointestinal symptoms in acromegaly: a case control study. World J Gastrointest Pharmacol Ther. 2020;11(2):17–24. doi:10.4292/wjgpt.v11.i2.17
   PubMedGoogle Scholar
• Gadelha MR, Gordon MB, Doknic M, et al. ACROBAT edge: safety and efficacy of switching injected SRLs to oral paltusotine in patients with acromegaly. J Clin Endocrinol Metab. 2023;108(5):e148–e159. doi: 10.1210/clinem/dgac643
   PubMed Web of Science ®Google Scholar
• Pavel M, Borson-Chazot F, Cailleux A, et al. Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study. Cancer Chemother Pharmacol. 2019;83(2):375–385. doi: 10.1007/s00280-018-3734-1
   PubMed Web of Science ®Google Scholar
• Octreotide Injection. ASHP. 2024 Jan 22 [cited 2024 Feb 19]. Available from: https://www.ashp.org/drug-shortages/current-shortages/drug-shortage-detail.aspx?id=229&loginreturnUrl=SSOCheckOnly
   Google Scholar
• Lim DST, Fleseriu M. Personalized medical treatment of patients with acromegaly: a review. Endocr Pract. 2022;28(3):321–332. doi:10.1016/j.eprac.2021.12.017
   PubMed Web of Science ®Google Scholar
• Melmed S, Kaiser UB, Lopes MB, et al. Clinical biology of the pituitary adenoma. Endocrine Reviews. 2022;43(6):1003–1037. doi: 10.1210/endrev/bnac010
   PubMed Web of Science ®Google Scholar
• van der Meulen M, Zamanipoor Najafabadi AH, Broersen LHA, et al. State of the art of patient-reported outcomes in acromegaly or GH deficiency: A systematic review and meta-analysis. J Clin Endocrinol Metab. 2022;107(5):1225–1238. doi: 10.1210/clinem/dgab874
   PubMed Web of Science ®Google Scholar